


What is Claim d is:

1. An acid addition salt of sertraline:



wherein said salt is selected from the group consisting of the p-toluenesulfonic acid salt, the
5 fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt
and the (-)-camphor-10-sulfonic acid salt.

2. The salt according to claim 1 wherein the salt is the p-toluenesulfonic acid
salt.

3. The salt according to claim 2 having an x-ray diffraction pattern characterized
10 substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2 θ of 16.6
degrees \pm 0.2 degrees as measured with copper radiation.

4. The salt according to claim 2 having an x-ray diffraction pattern characterized
substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an
angle of 2 θ degrees and d-spacings in Å, within the margins of error indicated, as measured
15 with copper radiation:

Angle 2 θ (\pm 0.2)	d-value (Å) (\pm 0.2)
6.5	13.6
16.1	5.5
16.6	5.3
20.0	4.4
23.7	3.8
24.0	3.7
25.8	3.5
28.5	3.1

5. The salt according to claim 2 characterized in having an onset of melting transition at about 260 °C.

6. The salt according to claim 1 wherein the salt is the fumaric acid salt.

7. The salt according to claim 6 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 15.5 degrees \pm 0.2 degrees as measured with copper radiation.

8. The salt according to claim 6 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in Å, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (\pm 0.2)	d-value (Å) (\pm 0.2)
13.9	6.4
15.5	5.7
18.3	4.8
19.1	4.6
20.8	4.3
23.0	3.9
23.4	3.8
27.4	3.2

9. The salt according to claim 6 characterized in having an onset of melting transition at about 187 °C.

10. The salt according to claim 1 wherein the salt is the benzenesulfonic acid salt.

11. The salt according to claim 10 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 19.8 degrees \pm 0.2 degrees as measured with copper radiation.

12. The salt according to claim 10 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in Å, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (\AA) (± 0.2)
7.5	11.9
15.1	5.9
22.4	4.0
22.9	3.9
23.4	3.8
24.4	3.6
24.8	3.6
27.9	3.2

13. The salt according to claim 10 characterized in having a solid-solid transition at about 185 °C and an onset of melting transition at about 230 °C.

14. The salt according to claim 1 wherein the salt is the benzoic acid salt.

5 15. The salt according to claim 14 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 16.1 degrees ± 0.2 degrees as measured with copper radiation.

10 16. The salt according to claim 14 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (\AA) (± 0.2)
14.9	5.9
16.1	5.5
18.0	4.9
18.5	4.8
19.3	4.6
23.6	4.4
25.0	3.6
25.2	3.5

17. The salt according to claim 14 characterized in having an onset of melting transition at about 154 °C.

18. The salt according to claim 1 wherein the salt is the L-tartaric acid salt.

15 19. The salt according to claim 18 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 15.0 degrees ± 0.2 degrees as measured with copper radiation.

20. The salt according to claim 18 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in Å, within the margins of error indicated, as measured with copper radiation:

5

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
13.7	6.5
15.0	5.9
16.7	5.3
18.4	4.8
20.5	4.3
22.1	4.0
22.9	3.9
24.5	3.6

21. The salt according to claim 22 characterized in having an onset of melting transition at about 184 °C.

22. The salt according to claim 1 wherein the salt is the (-)-camphor-10-sulfonic acid salt.

10

23. The salt according to claim 22 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 5.6 degrees ± 0.2 degrees as measured with copper radiation.

15

24. The salt according to claim 22 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in Å, within the margins of error indicated, as measured with copper radiation:

Angle 2 θ (\pm 0.2)	d-value (Å) (\pm 0.2)
5.6	15.8
13.1	6.8
14.6	6.1
15.8	5.6
18.2	4.9
19.9	4.5
21.7	4.1
22.6	3.9

25. The salt according to claim 22 characterized in having an onset of melting transition at about 265 °C.

26. A pharmaceutical composition comprising a salt according to claim 1 and a pharmaceutically acceptable carrier or excipient.

5 27. A method of treating in a mammal a disease, disorder or condition selected from the group consisting of aggression disorders; anxiety disorders, panic attack, agoraphobia, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder and acute stress disorder; cognitive disorders selected from the group consisting of
10 amnesic disorders, amnesic disorders due to a general medical condition, substance-induced persisting amnesic disorder and amnesic disorders not otherwise specified, deliriums, deliriums due to a general medical condition, substance-induced delirium and delirium not otherwise specified, dementias, dementia of the Alzheimer's type, vascular dementia, dementia due to a general medical condition; AIDS-, Parkinson's-, head trauma-,
15 and Huntington's-induced dementias; substance-induced persisting dementia, dementia due to multiple etiologies; depression disorders; emesis; epilepsy; food-related behavioral disorders, anorexia nervosa, bulimia; headache disorders, migraine; cluster and vascular headaches; learning disorders, attention deficit disorder, attention deficit/hyperactivity disorder; obesity; ocular disorders; platelet aggregation disorders; psychotic conditions, schizophrenia, paranoid-type schizophrenia, disorganized-type schizophrenia, catatonic-type
20 schizophrenia, undifferentiated-type schizophrenia, residual-type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorders due to a general medical condition; sleep disorders, primary sleep disorders, parasomnias, dyssomnias, sleep disorders related to
25 another mood and anxiety disorders, sleep disorders due to a general medical condition; sexual behavior disorders; substance-abuse disorders, alcohol-related disorders; alcohol-use disorders selected from dependence and abuse disorders; alcohol-induced disorders selected

from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnesic, mood, anxiety, sexual dysfunction, and sleep disorders; amphetamine-related disorders; amphetamine-use disorders selected from dependence and abuse disorders; amphetamine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction and sleep disorders; caffeine-related disorders selected from as intoxication, induced-anxiety disorder, induced-sleep disorder; cannabis-related disorders, cannabis-use disorders selected from abuse and dependence disorders; cannabis-induced disorders selected from intoxication, intoxication delirium, psychotic disorder, and anxiety disorders; cocaine-related disorders; cocaine-use disorders selected from dependence and abuse disorders; cocaine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction, sleep disorder; hallucinogen-related disorders, hallucinogen-use disorders selected from dependence and abuse disorders; hallucinogen-induced disorders selected from intoxication, persisting perception, intoxication delirium, psychotic, mood, and anxiety disorder; inhalant-related disorders, inhalant-use disorders selected from dependence and abuse disorders; inhalant-induced disorders selected from intoxication, intoxication delirium, persisting dementia, psychotic, mood, and anxiety disorder; nicotine-related disorders selected from dependence and withdrawal; opioid-related disorders, opioid-use disorders selected form dependence and abuse disorders; opioid-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, sexual dysfunction, and sleep disorder; phencyclidine-related disorders, phencyclidine-use disorders selected from dependence and abuse disorder; phencyclidine-induced disorders selected from intoxication, intoxication delirium, psychotic, mood, and anxiety disorder; sedative-, hypnotic- or anxiolytic-related disorders, sedative-use disorders selected from dependence and abuse disorders; sedative-induced disorders selected from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnesic, psychotic, mood, anxiety, sexual dysfunction, and sleep disorders; polysubstance-related disorder, vision disorders, and glaucoma; comprising administering to a subject in need thereof a therapeutically effective amount of a salt according to claim 1.

30